News and Events September 12, 2024: BioAegis Therapeutics to Present at Upcoming MedInvest Biotech & Pharma Investor Conference in NYC Read More » February 27, 2024: BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS) Read More » October 16, 2023: BioAegis Therapeutics Awarded $20 Million BARDA DRIVe Contract to Advance Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS) Read More » May 2023: BioAegis Therapeutics to Sponsor a Webinar, Below the Eyes of the Hippopotamus: The Expanding Spectrum of Auto- and Hyper- Inflammatory Diseases Read More » April 2023: BioAegis Therapeutics Announces Two Studies Exploring the Role of ‘Inflammation Regulator’ Gelsolin in Type 2 Diabetes Read More » January 2023: BioAegis Therapeutics Announces FDA Clearance of IND for its ‘Inflammation Regulator Protein,’ Gelsolin, for the Treatment of ARDS Read More » « Previous Page1 Page2 Page3 Page4 … Page6 Next » March 18-21, 2025: 44th Annual International Symposium on Intensive Care and Emergency Medicine (ISICEM) Learn More » March 27-28, 2025: MedInvest Biotech & Pharma Investor Conference Learn More » Articles: Insights, intelligence and opinions from our experts. A Pioneering Biotech Promises to Revolutionize Medicine with a Human Protein that Boosts the Body’s Immune System BioAegis Therapeutics expects to unlock the healing powers of gelsolin and develop new treatments for disease. Host-directed Therapeutics for the Next Pandemic: What They Are and Why We'll Need Them by Dr. Lester Kobzik, Chief Scientific Advisor and Professor (emeritus) of Pathology at The Harvard Medical School Sepsis: The Hydra Within Us As Wallstreet Funding for Sepsis Research has Evaporated US Government Funding Picks Up the Slackby Steven Cordovano, Co-founder, VP Business Development Vaccines Alone Are Not The Answer The US is overlooking Covid’s main culprit — the threat that vaccines do not address.by Susan L. Levinson, PhD., Co-founder and CEO
September 12, 2024: BioAegis Therapeutics to Present at Upcoming MedInvest Biotech & Pharma Investor Conference in NYC Read More »
February 27, 2024: BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS) Read More »
October 16, 2023: BioAegis Therapeutics Awarded $20 Million BARDA DRIVe Contract to Advance Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS) Read More »
May 2023: BioAegis Therapeutics to Sponsor a Webinar, Below the Eyes of the Hippopotamus: The Expanding Spectrum of Auto- and Hyper- Inflammatory Diseases Read More »
April 2023: BioAegis Therapeutics Announces Two Studies Exploring the Role of ‘Inflammation Regulator’ Gelsolin in Type 2 Diabetes Read More »
January 2023: BioAegis Therapeutics Announces FDA Clearance of IND for its ‘Inflammation Regulator Protein,’ Gelsolin, for the Treatment of ARDS Read More »
March 18-21, 2025: 44th Annual International Symposium on Intensive Care and Emergency Medicine (ISICEM) Learn More »